There are several entries in the MNTA ReadMeFirst (#msg-96385440) devoted to Teva’s thrice-weekly Copaxone, so I have nothing to say about it here except to re-iterate that the new thrice-weekly drug is not directly substitutable for regular (daily) Copaxone.
(The latest version of the MNTA ReadMeFirst can always be accessed from the red button on the main screen of this message board.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”